| Identification | Back Directory | [Name]
LY-518674 | [CAS]
425671-29-0 | [Synonyms]
LY-674
LY-518674
PNHFDVSKDSLUFH-UHFFFAOYSA-N
2-Methyl-2-[4-[3-[1-(4-Methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid
Propanoic acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl-
Peroxisome proliferator-activated receptors,inhibit,PPAR,Inhibitor,LY-518674,LY 674,LY674,LY518674,LY 518674,PPARα,atherosclerosis | [Molecular Formula]
C23H27N3O4 | [MDL Number]
MFCD11977271 | [MOL File]
425671-29-0.mol | [Molecular Weight]
409.48 |
| Hazard Information | Back Directory | [Uses]
LY518674 is a potent, selective PPARα agonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis[1][2][3]. | [in vivo]
LY518674 reduces triglycerides and increased HDL-C in vivo[2].
LY518674 substantially increases apolipoprotein A-I (apoA-I) turnover without major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3].
| [References]
[1] Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. DOI:10.1016/j.bmcl.2014.03.090
[2] Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73. DOI:10.1001/jama.297.12.1362
[3] Khera AV, et al. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2. DOI:10.1093/eurheartj/ehv291 |
|
|